Oncocyte CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Broadwood Partners, L.P. has increased its beneficial ownership in Insight Molecular Diagnostics Inc. to 39.7% following a series of open-market share purchases.
Broadwood Partners increased its beneficial ownership in Insight Molecular Diagnostics Inc. to 37.4% through a $3 million registered direct offering.
SCHEDULE 13D/A: Broadwood Capital Boosts Stake in Oncocyte Corp Through $10.6 Million Private Placement and Registered Direct Offering
Broadwood Capital and its affiliates have significantly increased their beneficial ownership in Oncocyte Corp to 40.2% through a $10.6 million private placement and registered direct offering at $2.05 per share.